289 results on '"Gomberg-Maitland M"'
Search Results
2. Prognostic Value of the Multicomponent Improvement (MCI) Endpoint in Patients With Pulmonary Arterial Hypertension (PAH) Treated With Sotatercept
3. Consistency of the Efficacy and Safety Profile of Sotatercept across Baseline Cardiac Index Subgroups: A Pooled Analysis of STELLAR and PULSAR Trials
4. Uptitration of Pulmonary Arterial Hypertension Therapies: Transition From Oral Selexipag to Parenteral Treprostinil
5. Sleep-Related Hypoxia, Right Ventricular Dysfunction, and Survival in Patients With Group 1 Pulmonary Arterial Hypertension
6. Effect of sotatercept on multicomponent improvement in the PULSAR study
7. PULSAR Open-Label Extension: Long-Term Efficacy and Safety of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (PAH)
8. (1209) - Uptitration of Pulmonary Arterial Hypertension Therapies: Transition From Oral Selexipag to Parenteral Treprostinil
9. Predictive Value of Troponin, NTproBNP and Sodium on Adverse Clinical Outcomes in COVID-19
10. PULSAR Study Open-Label Extension: Interim Results from a Phase 2 Study of the Efficacy and Safety of Sotatercept When Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension (PAH)
11. Biomarkers Associated with Cardiovascular Morbidity and Mortality in COVID-19 Patients
12. (161) - Consistency of the Efficacy and Safety Profile of Sotatercept across Baseline Cardiac Index Subgroups: A Pooled Analysis of STELLAR and PULSAR Trials.
13. Imaging in dysynchrony and ventricular function: Techniques
14. Poster session: Dobutamine stress echo
15. The management of pregnancy and pregnancy-related medical conditions in pulmonary arterial hypertension patients
16. The Impact of Stratification by Baseline Pulmonary Arterial Hypertension Risk Score - Analysis from the Freedom-EV Study
17. An Analysis of FREEDOM-EV Using the French Noninvasive and Reveal 2.0 Risk Stratification Criteria
18. Registries and randomised controlled trials in pulmonary arterial hypertension: are they revealing?
19. A Dosing/Cross-Development Study of the Multikinase Inhibitor Sorafenib in Patients With Pulmonary Arterial Hypertension
20. Highlights from the new pulmonary hypertension classification and guidelines 2009
21. Have we found the hidden treasure? End-points in PAH trials
22. The evolving epidemiology of pulmonary arterial hypertension
23. Intravenous catheter infections in pulmonary arterial hypertension
24. New targets for pulmonary hypertension: gene and stem cell therapy
25. Whatʼs new in pulmonary hypertension?
26. Delivery of intravenous treprostinil at low infusion rates using a miniaturized infusion pump in patients with pulmonary arterial hypertension
27. ABI-009, nab-Sirolimus, an mTOR Inhibitor with High Lung Accumulation in Preclinical Models Is Active in Patients with Severe Pulmonary Arterial Hypertension
28. Severe Pulmonary Arterial Hypertension Treated with ABI-009, nab-Sirolimus, an mTOR Inhibitor
29. Ralinepag, an Oral, Selective, Prostacyclin (IP) Receptor Agonist Consistently Improved Mortality Risk Scores Derived From PAH Registries Across Three Regions: Phase 2 Study Analysis
30. Updated Risk Score Calculator for Pulmonary Arterial Hypertension Patients
31. Content Validation of the Pulmonary Arterial Hypertension Symptoms and Impact (PAH-SYMPACT ® ) Questionnaire
32. Psychometric Validation of the Pulmonary Arterial Hypertension Symptoms and Impact (PAH-SYMPACT ® ) Questionnaire
33. Applying Rasch analysis to evaluate measurement equivalence of different administration formats of the Activity Limitation scale of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR)
34. A Coding Polymorphism in PFAS (The Gene Encoding Phosphoribosylformylglycinamidine Synthase) Is a Determinant of Prostacyclin Dose
35. (502) - Ralinepag, an Oral, Selective, Prostacyclin (IP) Receptor Agonist Consistently Improved Mortality Risk Scores Derived From PAH Registries Across Three Regions: Phase 2 Study Analysis
36. The Potential Utility of Serial NT-proBNP Measurements in Determining a Therapeutic Response in Group I Pulmonary Artery Hypertension
37. Three-Dimensional Analysis of Septal Curvature from Cardiac Magnetic Resonance Images for the Evaluation of Severity of Pulmonary Hypertension
38. Beta-Blocker Therapy Is Not Associated with Adverse Outcomes in Pulmonary Arterial Hypertension
39. Totally Implantable IV Treprostinil Therapy in Pulmonary Arterial Hypertension: Assessment of the Implantation Procedure
40. Measuring health in pulmonary hypertension: emphasising the right end-point?
41. PRM171 - Content Validation of the Pulmonary Arterial Hypertension Symptoms and Impact (PAH-SYMPACT®) Questionnaire
42. PRM154 - Psychometric Validation of the Pulmonary Arterial Hypertension Symptoms and Impact (PAH-SYMPACT®) Questionnaire
43. Assessing Measurement Equivalence of Different Forms of Administration of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) Using Rasch Analysis
44. Three-dimensional modeling of the right ventricle from two-dimensional transthoracic echocardiographic images: utility of knowledge-based reconstruction in pulmonary arterial hypertension
45. Cost-Effective Design of Pulmonary Arterial Hypertension Trials To Detect Changes in Right Ventricular Size and Function: 3D Echocardiography Versus Cardiovascular Magnetic Resonance
46. Survival in Pulmonary Arterial Hypertension Patients Awaiting Transplant
47. Errata
48. Imaging in dysynchrony and ventricular function: Techniques
49. 55 RePHerral Study: A Multi-Center Study on the Referral of Pulmonary Hypertension Patients
50. 826 RePHerral Study: A Multi-Center Study on the Referrals for Pulmonary Hypertension (PH); Left Heart Disease and PH
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.